当前位置:首页 - 行情中心 - 振东制药(300158) - 财务分析 - 现金流量表

振东制药

(300158)

  

流通市值:53.45亿  总市值:53.49亿
流通股本:9.92亿   总股本:9.92亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,019,135,366.49461,491,033.722,580,213,730.061,822,908,395.79
  收到的税费返还4,009,856.744,000,00023,352,697.1421,352,286.73
  收到其他与经营活动有关的现金16,668,103.7211,874,428.3728,052,239.7327,844,827.77
  经营活动现金流入小计1,039,813,326.95477,365,462.092,631,618,666.931,872,105,510.29
  购买商品、接受劳务支付的现金422,298,068.57225,753,203.491,246,258,685.43859,989,462.17
  支付给职工以及为职工支付的现金278,162,766.84135,217,681.3537,330,984.65359,753,615.16
  支付的各项税费61,618,780.3320,017,692.57182,355,521.35137,371,150.89
  支付其他与经营活动有关的现金625,625,290.46400,438,761.161,126,153,202.311,117,728,132.64
  经营活动现金流出小计1,387,704,906.2781,427,338.523,092,098,393.742,474,842,360.86
  经营活动产生的现金流量净额-347,891,579.25-304,061,876.43-460,479,726.81-602,736,850.57
二、投资活动产生的现金流量:
  收回投资收到的现金1,308,211,646.12597,000,0003,012,919,6002,626,599,000
  取得投资收益收到的现金6,645,931.582,862,868.1712,867,180.8610,752,321.84
  处置固定资产、无形资产和其他长期资产收回的现金净额--59,947.131,024,266.13
  投资活动现金流入小计1,314,857,577.7599,862,868.173,025,846,727.992,638,375,587.97
  购建固定资产、无形资产和其他长期资产支付的现金35,744,130.9719,561,814.41179,124,007.07119,587,834.69
  投资支付的现金1,309,000,000673,000,0002,550,022,2002,127,354,900
  投资活动现金流出小计1,344,744,130.97692,561,814.412,729,146,207.072,246,942,734.69
  投资活动产生的现金流量净额-29,886,553.27-92,698,946.24296,700,520.92391,432,853.28
三、筹资活动产生的现金流量:
  取得借款收到的现金148,664,633.58148,384,300162,158,486.5-
  收到其他与筹资活动有关的现金6,713,553.443,509,752.0436,455,079.6533,210,307.3
  筹资活动现金流入小计155,378,187.02151,894,052.04198,613,566.1533,210,307.3
  偿还债务支付的现金--33,965,173.0333,637,400
  分配股利、利润或偿付利息支付的现金2,559,475.111,008,244.37713,077.28148,348.21
  支付其他与筹资活动有关的现金4,544,411.121,735,783.6266,303,513.2362,831,992.45
  筹资活动现金流出小计7,103,886.232,744,027.99100,981,763.5496,617,740.66
  筹资活动产生的现金流量净额148,274,300.79149,150,024.0597,631,802.61-63,407,433.36
五、现金及现金等价物净增加额-229,503,831.73-247,610,798.62-66,147,403.28-274,711,430.65
  加:期初现金及现金等价物余额491,867,869.21491,867,869.21558,015,272.49558,015,272.49
  期末现金及现金等价物余额262,364,037.48244,257,070.59491,867,869.21283,303,841.84
补充资料:
  净利润-95,301,962.62--303,086,623.19-
  资产减值准备40,387,090.48-5,597,299.55-
  固定资产和投资性房地产折旧44,795,261.37-89,075,688.96-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧44,795,261.37-89,075,688.96-
  无形资产摊销12,592,606.39-25,508,052.43-
  长期待摊费用摊销9,716,902.53-11,851,010.56-
  处置固定资产、无形资产和其他长期资产的损失--633,441.94-
  固定资产报废损失4,120.52-143,074.28-
  公允价值变动损失-251,967.83--1,586,150.58-
  财务费用3,027,189.96-2,207,915.59-
  投资损失-330,970.02--10,781,530.12-
  递延所得税-3,102,430.12--3,015,355.81-
  其中:递延所得税资产减少-2,118,158.19--3,160,732.42-
    递延所得税负债增加-984,271.93-145,376.61-
  存货的减少28,909,950.33-237,151,549.57-
  经营性应收项目的减少70,290,576.27--164,535,938.25-
  经营性应付项目的增加-458,255,174.82--347,966,034.3-
  其他-1,074,585.98--3,086,630.07-
  现金的期末余额262,364,037.48-491,867,869.21-
  减:现金的期初余额491,867,869.21-558,015,272.49-
  现金及现金等价物的净增加额-229,503,831.73--66,147,403.28-
公告日期2026-08-262026-04-212026-04-212025-10-23
审计意见(境内)标准无保留意见
TOP↑